Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-24 @ 9:19 PM
Ignite Modification Date:
2025-12-25 @ 7:06 PM
NCT ID:
NCT02713204
Pre Assignment Details:
Out of 560 participants, 365 were randomized \& treated. Participants were randomized in 1:2:3 to receive REGN910-3 3:2mg, REGN910-3 6:2mg \& 2mg intravitreal aflibercept injection (IAI) followed by re-randomization at week 12 in REGN910-3 6:2mg \& IAI 2mg arm. Not all participants who completed Week 12 were re-randomized \& continued to Week 36.
Recruitment Details:
The study was conducted at 87 sites in the United States. A total of 560 participants were screened in the study.
Study:
NCT02713204
Study Brief:
Results Section:
NCT02713204